Comparison

Plozalizumab (CCR2/CD192) Antibody, Monoclonal

Item no. PRS-10-734-0.1mg
Manufacturer ProSci
Amount 0.1 mg
Category
Type Antibody Monoclonal
Specific against other
Isotype IgG1 Kappa
Conjugate/Tag Unconjugated
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Alias MLN-1202,anti-CCR2,hu1D9
Available
Shipping Temperature
blue ice or room temperature
Storage Conditions
Store at -80°C
Manufacturer - Research Area
Drug Analogues
Background
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis.
Purification
>95%
Buffer
PBS buffer pH7.5
Immunogen
Humanized / CCR2/CD192 [Homo sapiens]
Clonality
Monoclonal
NCBI Organism
homo sapiens
Disclaimer
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 0.1 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close